Argentine approval prompts new promotion of Sputnik Light

6 December 2021

The one-shot Sputnik Light jab against COVID-19 has been approved by the Ministry of Health of Argentina as a standalone vaccine and a booster shot.

Sputnik Light is based on human adenovirus serotype 26, which is the first component of Russia’s Sputnik V vaccine that has been approved in many parts of the world.

Argentina was one of the first countries to authorize Sputnik V in December of 2020 and it has been one of the most commonly-used vaccines during the nation’s vaccination campaign.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK